SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA issues warning letter to Divis Labs’ Vishakhapatnam facility

24 Apr 2017 Evaluate

United States Food and Drug Administration (USFDA) has issued a warning letter to Divis Laboratories’ Unit-II at Vishakhapatnam facility. The company along with external consultants and subject matter experts is working to address the concerns of USFDA and is making all efforts to fully meet the compliance requirements.

The company has responded to USFDA inspection observations with an appropriate remediation process to overcome the deficiencies observed.

Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.

Divis Laboratories Share Price

7258.05 -61.70 (-0.84%)
17-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1933.10
Dr. Reddys Labs. 1210.85
Cipla 1418.40
Lupin 2442.10
Zydus Lifesciences 1142.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: